)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Schrödinger
Schrödinger (SDGR) investor relations material
Schrödinger Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 revenue rose 19% YoY to $64.5M; ACV was $44.7M, up 17%, or 24% excluding contribution ACV. FY26 ACV and drug discovery revenue guidance increased.
Hosted adoption and a Structure Therapeutics milestone supported results; operating loss narrowed, while the net loss widened on equity-investment fair-value losses.
Financial highlights
Q3 total revenue was $64.5M versus $54.3M; gross profit was $38.3M versus $28.0M, and operating loss was $26.1M versus $45.9M.
Operating expenses were $64.4M, down 13% YoY; net loss was $37.7M versus $32.8M, with diluted loss per share of $0.50 versus $0.45.
Other expense included a $14.8M fair-value loss on equity investments; contribution revenue declined 60% to $2.1M as initial predictive-toxicology grant funding was completed.
9M revenue was $182.0M versus $168.6M; net loss narrowed to $91.8M from $135.8M.
Outlook and guidance
FY26 ACV guidance increased to $222M–$232M, implying 12%–17% growth over 2025; drug discovery revenue guidance rose to $75M–$85M from $65M–$75M.
FY26 operating expenses are expected below 2025; existing cash and securities are expected to cover operating and capital needs for at least 24 months.
Hosted-software transitions shift revenue recognition over contract terms and may contribute to near-term revenue declines.
2028 objectives include 10%–15% annual ACV growth, gross margin returning to the high 70s, $50M annual drug discovery revenue, and positive adjusted EBITDA by year-end.
Full commercial release of Bunsen was expected by year-end 2026; predictive toxicology capabilities were being made more broadly available during 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Schrödinger
- AI-driven platform innovation and hosted solutions fuel growth, with profitability targeted by 2028.SDGR
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 saw 27% ACV growth, $58.9M revenue, and a return to profitability.SDGRQ2 2026
- Shifting to R&D and partnerships, with robust revenue growth and key clinical data ahead.SDGRJefferies London Healthcare Conference 2025
- All proposals passed and strategic focus remains on AI-driven molecular discovery innovation.SDGRAGM 2026
- Early-stage AI and computational tools are driving growth and transforming drug discovery.SDGRRBC Capital Markets Global Healthcare Conference 2026
- 23% revenue growth to $255.9M, strong cash, and hosted transition target positive EBITDA by 2028.SDGRQ4 2025
- Major Novartis deal and advancing clinical pipeline position the company for strong growth.SDGRJefferies London Healthcare Conference 2024
- Q2 revenue up 35% to $47.3M; net loss $54M; Gates grant and pipeline drive growth.SDGRQ2 2024
- Novartis deal, strong software growth, and $398.4M cash offset lower drug discovery revenue.SDGRQ3 2024
Next Schrödinger earnings date
UBS Global Healthcare Conference10 Nov, 2026
Schrödinger
Next Schrödinger earnings date
UBS Global Healthcare Conference10 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The Company's solutions enable life science researchers to identify likeliest candidates from compound libraries and screen them against biological targets in the systems biology environment. Schrödinger Inc. was founded in 1990 and is based in New York.